What to Expect this Week: 7/14

July 13, 2025

Welcome!

A big shoutout to all of our new subscribers — happy you’re joining us @OfftheTicker.

For some companies that have earnings this week, we wanted to choose a couple and want to highlight some notable achievements or developments from the past few months that stand out. Also an analysis of their financial outlook for the upcoming year (2025) based on available data. Finally, we will share our take on whether the stock might be a good buy and were we might see it going this year.

Weekly Earnings Spotlight: July 14-18th, 2025

Monday June 14th: JP Morgan Chase(JPM), Bank of America (BAC), UnitedHealthGroup (UNH)

Tuesday July 15th: Citigroup(C), Wells Fargo (WFC), Charles Schwab (SCHW)

Thursday July 17: Taiwan Semiconductor Manufacturing (TSM), Abbott Laboratories (ABT)

Friday July 18th: American Express (AXP), 3M (MMM)

🏦 JPMorgan Chase (JPM)

Recent Highlights:


JPMorgan Chase, the largest U.S. bank by assets, faces a challenging quarter amid a tougher macroeconomic backdrop. While the bank delivered strong earnings in previous quarters, Q2 2025 is expected to reflect headwinds from softer investment banking activity and a slowdown in capital markets amid ongoing geopolitical tensions and inflation concerns.

  • Investment banking fees, which represent a significant revenue stream, are forecasted to decline by mid-teens percentage year-over-year due to reduced dealmaking volume and market volatility.

  • Net interest income is expected to remain stable, supported by the Federal Reserve's continued elevated interest rate environment, which benefits JPM’s lending business.

  • Loan growth is modest, with commercial lending growth tempered by cautious corporate spending.

  • JPMorgan’s strong risk management practices continue to mitigate credit losses, though some elevated provisions for loan losses remain possible in uncertain economic conditions.

  • The bank continues to build its digital banking platforms and expand wealth management, which are strategic growth areas with strong long-term potential

Financial Guidance:

While Q2 earnings per share (EPS) estimates hover around $4.47, down from $6.44 a year earlier, JPMorgan remains confident in its diversified business model. The bank expects to maintain a robust capital position with a Tier 1 capital ratio near 13%. JPM plans to continue share repurchases, which supports earnings per share and shareholder returns. Operating expenses may rise slightly due to investments in technology and compliance. The bank also forecasts loan growth to stabilize as the economy navigates uncertainties.

Stock Outlook:


JPMorgan stock trades near $288.19, with a price-to-earnings (P/E) ratio around 13.8, notably below the S&P 500 average (~22). This discount signals potential undervaluation relative to its peers. Analyst consensus price targets average near $300, reflecting moderate upside but cautious sentiment given the challenging economic backdrop. Investors should watch for JPM’s ability to grow fees in wealth management and trading to offset slower investment banking and maintain credit quality in an uncertain environment. We are not currently invested in any financial institutions other than SOFI and Robinhood and do not plan to add any positions to any large banks due to growth concerns and complacency in the industry.

🏥 UnitedHealth Group (UNH)

Recent Highlights:


UnitedHealth Group, the largest health insurer and managed care provider in the U.S., has encountered some headwinds from rising medical costs and shifts in healthcare utilization patterns.

  • The company’s latest earnings reflect higher-than-expected claims costs driven by an aging and sicker insured population, increasing utilization of expensive healthcare services.

  • UnitedHealth has revised down its full-year 2025 earnings guidance due to these cost pressures but maintains confidence in its Optum division (health services and pharmacy benefits management), which continues to deliver strong growth.

  • Optum’s diversified revenue streams, including care delivery and technology solutions, provide resilience against insurer margin pressures.

  • UNH is investing heavily in data analytics and AI to improve care management and reduce avoidable costs.

Financial Guidance:

The revised full-year 2025 EPS guidance range is $24.65 to $25.15, with adjusted EPS expected between $26 and $26.50. Despite the downward revisions, UnitedHealth plans to invest in expanding Medicare Advantage membership and enhancing pharmacy benefit offerings. The company targets a modest increase in revenue growth, but margin pressures will likely persist through the year, impacting near-term profitability.

Stock Outlook:

Trading around $299.51, UnitedHealth’s stock P/E ratio stands near 13.2, below its historical average and the broader market, suggesting potential value. However, investor sentiment remains cautious due to ongoing cost challenges and regulatory uncertainty in healthcare. Analysts view UNH as a long-term winner given its scale, innovation in health services, and strong free cash flow generation but advise monitoring margins closely. We will be adding to our position in UNH before earnings with hopes that the stock will grow its PE ratio. We think that this stock is way undervalued compared to the rest of the healthcare industry.

💻 Taiwan Semiconductor Manufacturing Company (TSM)

Recent Highlights:

TSMC remains a dominant force in the semiconductor foundry space, capitalizing on surging demand for advanced chips, particularly those used in AI applications.

  • Q2 2025 sales surged 39% year-over-year to NT$933.8 billion (approx. US$31.93 billion), exceeding consensus estimates.

  • The company sees AI chips as a major growth driver, forecasting AI-related revenue to double in 2025 and sustain a mid-40% compound annual growth rate over the next five years.

  • TSMC’s leadership in 5-nanometer and 3-nanometer process technologies strengthens its position among key customers like Apple, Nvidia, AMD, and Qualcomm.

  • Capacity expansion projects remain on track, with capital expenditures planned at $36–40 billion for 2025 to support next-generation chip production.

  • Geopolitical risks persist, particularly U.S.-China tensions and potential supply chain disruptions, but TSMC’s diversified customer base and geographic footprint mitigate some risks.

Financial Guidance:

Analysts expect Q2 EPS of $2.13 and revenue near $28.5 billion, reflecting strong volume and pricing power. Operating margins are projected to expand slightly due to scale efficiencies and premium product mix. TSMC’s balance sheet remains strong with minimal debt, supporting aggressive R&D and capex spending.

Stock Outlook:

Trading around $229.76, TSMC’s stock is positioned for upside, with consensus price targets near $270. The company’s dominant market share, technological edge, and critical role in AI chip supply chains underpin optimism. Investors should watch for TSMC’s ability to navigate geopolitical risks and sustain capital investment without diluting returns. We currently own a small amount of Taiwan Semiconductor but are very cautious in adding to our position due to the foreign currency loss that we are seeing from the Taiwan dollar against the USD as well as the possible invasion from China looming.

🏭 3M (MMM)

Recent Highlights:

3M, a diversified industrial conglomerate, is working through supply chain pressures and tariff-related cost headwinds.

  • In Q1 2025, 3M delivered EPS of $1.88, beating estimates despite challenges. The company raised full-year EPS guidance to $7.60 to $7.90, factoring in expected tariffs and logistical costs of up to $220 million.

  • 3M is implementing strategic shifts including production relocations, supply chain diversification, and automation to mitigate cost pressures.

  • Growth drivers include safety and industrial products, healthcare, and electronics, though inflation and raw material costs remain concerns.

  • The company is also focusing on innovation and portfolio optimization to improve margins.

Financial Guidance:

3M’s 2025 capital expenditures are expected to be near $1.5 billion, supporting new product development and facility upgrades. The company projects moderate revenue growth and aims to improve operating margins through cost management initiatives. Tariff and inflation risks remain the main downside concerns.

Stock Outlook:

At $157.32, 3M’s stock trades at a discount to the broader industrial sector, with analysts projecting a target price near $170. The stock offers modest upside potential for investors confident in 3M’s restructuring efforts and ability to navigate cost challenges. Monitoring tariff impacts and supply chain progress will be key near-term factors. Tariff concerns continuing throughout the year are keeping us out of 3M at the moment.

Note: OffTheTicker provides general information and opinions on markets, stocks, and ETFs for educational purposes only. We are not financial advisers, and our content does not constitute personalized investment advice. Investing involves risks, including potential loss of principal. Always consult a qualified financial adviser before making investment decisions. Past performance is not indicative of future results. OffTheTicker is not responsible for any financial losses or decisions made based on our content. All data is sourced as of June 17, 2025, and subject to change.